相关临床试验
123
34 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
进行中（未招募）
23
18.7%
已完成
39
31.7%
尚未招募
11
8.9%
招募中
17
13.8%
暂停
2
1.6%
终止
10
8.1%
Unknown
17
13.8%
撤回
4
3.3%
暂无批准数据
- The MANIFEST IO prospective study has recruited its first patient, marking a major milestone for the UK-wide platform launched in Q4 2024. - The study aims to recruit 3,000 patients across the UK starting immunotherapy for breast, bladder, kidney cancer, and melanoma. - Researchers will perform deep clinical and biological profiling to understand why some patients benefit more from immunotherapy and why toxicities occur. - The platform seeks to discover predictive biomarkers and new therapeutic targets to enable more precise, effective, and better-tolerated immunotherapies.
- Kate, the Princess of Wales, visited The Christie NHS Foundation Trust in Manchester, England, over one year after announcing her own cancer was in remission. - The Christie treats more than 60,000 patients annually and offers complementary holistic care services including therapy programs, art classes, and wellbeing spaces. - Kate toured the Teenage and Young Adult Unit, participated in an art session with patients, and visited the center's wellbeing garden designed for reflection and relaxation. - The visit underscores Kate's ongoing commitment to highlighting emotional and mental health support services that accompany cancer diagnosis, treatment, and recovery.
- University of Oxford researchers gain MRC funding and access to the DAWN supercomputer to develop AI-designed personalised mRNA cancer vaccines through the UK Cancer Vaccine AI & Supercomputing Project. - Cancer Research UK increases annual investment in its Manchester Institute by £6 million, bringing total funding to over £17 million, to expand immunology, immunotherapy, and AI-powered cancer research. - The Oxford-led consortium, now over 2,500 members, uses the CIARA AI scientist platform to analyse tumour biology and predict vaccine targets capable of generating strong anti-cancer immune responses. - The Manchester funding will create up to 100 new research jobs and support studies into how inflammation, the gut microbiome, and lab-grown white blood cells influence cancer treatment outcomes.
- A new clinical trial using proton beam therapy for mesothelioma patients aims to increase two-year survival rates from 30% to 50%, offering "realistic hope" for those with this aggressive asbestos-related cancer. - The trial is recruiting up to 148 patients across 23 NHS centres in England and Wales, with participants receiving daily proton beam therapy for five weeks at specialized facilities in London or Manchester. - Mesothelioma affects approximately 2,700 people annually in the UK, with over 70,000 deaths recorded since the 1980s, making this precision radiation approach particularly significant for patients ineligible for standard treatments.
- Poolbeg Pharma's POLB 001 trial will be central to the RISE programme, a £3.4 million MRC-funded initiative led by The University of Manchester and The Christie NHS Foundation Trust to address cytokine release syndrome in cancer immunotherapy. - The p38-MAP-kinase inhibitor POLB 001 aims to prevent CRS, which affects 50-90% of patients receiving bispecific antibody and CAR-T cell therapies, potentially making these breakthrough treatments safer and more accessible. - Poolbeg serves as lead business partner alongside Johnson & Johnson, which will provide the bispecific antibody teclistamab for the Phase IIa TOPICAL trial, with results expected in summer 2026.
- Zelluna received positive feedback from the UK's MHRA for its allogeneic TCR-NK cell therapy ZI-MA4-1, clearing the regulatory pathway for clinical development. - The company plans to file a Clinical Trial Application by year-end 2025 and initiate first-in-human trials in 2026 at leading UK cancer centers. - ZI-MA4-1 combines NK cell killing power with TCR precision targeting of MAGE-A4 antigen, designed to overcome limitations in solid tumor treatment. - The Phase I trial will be led by Professor Fiona Thistlethwaite at The Christie NHS Foundation Trust with participation from The Royal Marsden.
- Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment. - The UK's TORPEdO trial found no significant differences in side effects between proton beam therapy and IMRT in 205 patients, with both treatments showing similar outcomes for taste, swallowing, and quality of life measures. - Memorial Sloan Kettering's phase 2 trial demonstrated that proton beam therapy significantly reduced acute mucositis (7.5% vs 22.2%) and taste dysfunction while maintaining comparable survival rates in 98 patients. - Both studies achieved similar three-year survival rates exceeding 90%, but differed in their assessment of treatment-related toxicities and patient-reported quality of life outcomes.
- Poolbeg Pharma has secured Accelerating Clinical Trials Limited to conduct the POLB 001 Phase 2a trial and obtained free supply of an approved bispecific antibody drug for the study. - The TOPICAL trial will evaluate POLB 001's ability to reduce cytokine release syndrome in approximately 30 relapsed/refractory multiple myeloma patients at The Christie NHS Foundation Trust and other UK cancer centers. - POLB 001 aims to transform cancer immunotherapy delivery by enabling safer administration in community hospitals rather than specialized centers, potentially expanding patient access to life-saving treatments. - The company targets a market opportunity exceeding $10 billion for cytokine release syndrome prevention, with interim trial data expected in summer 2026.
- DEP-SN38, a dendrimer nanoparticle formulation of topoisomerase I inhibitor SN38, demonstrated encouraging anticancer activity in 114 heavily pretreated patients with advanced solid tumors including ovarian, colorectal, pancreatic, and breast cancers. - The study established a recommended phase 2 dose of 12.5mg/m2 with significantly lower rates of severe gastrointestinal toxicity and no cholinergic toxicity compared to irinotecan. - Patients showed signals of prolonged benefit despite having received a median of 4 prior therapy lines, with many able to return to work and everyday activities during treatment. - The dendrimer nanotechnology platform leverages enhanced permeability and retention effects in tumor microenvironments, potentially offering broader applications for oncology drug development.
- The groundbreaking LION trial investigates the combination of celecoxib with immunotherapy to treat advanced triple-negative breast cancer, non-small cell lung cancer, and renal cell carcinoma. - Led by The Christie NHS Foundation Trust, the trial aims to recruit 89 patients across six UK sites, with 11 patients already enrolled in this innovative treatment approach. - The study, funded by The Christie Charity and The Jon Moulton Charity Trust, explores whether reducing inflammation can enhance immunotherapy's effectiveness in fighting cancer.
